These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1760628)

  • 1. Endocrine problems in children after bone marrow transplant for hematologic malignancies. The Long-term Follow-up Team.
    Sanders JE
    Bone Marrow Transplant; 1991; 8 Suppl 1():2-4. PubMed ID: 1760628
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endocrinal sequela in bone marrow transplantations during childhood and adolescence].
    Le Heup B; von Bueltzingloewen A; Bordigoni P; Sommelet D; Pierson M
    Ann Pediatr (Paris); 1993 Sep; 40(7):463-8. PubMed ID: 8239398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
    Afify Z; Shaw PJ; Clavano-Harding A; Cowell CT
    Bone Marrow Transplant; 2000 May; 25(10):1087-92. PubMed ID: 10828870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine function after bone marrow transplantation for thalassemia.
    Galimberti M; De Sanctis V; Lucarelli G; Polchi P; Angelucci E; Baronciani D; Vullo C; Bagni B
    Bone Marrow Transplant; 1991; 7 Suppl 2():74. PubMed ID: 1878729
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth and development following marrow transplantation for leukemia.
    Sanders JE; Pritchard S; Mahoney P; Amos D; Buckner CD; Witherspoon RP; Deeg HJ; Doney KC; Sullivan KM; Appelbaum FR
    Blood; 1986 Nov; 68(5):1129-35. PubMed ID: 3533180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadal function in adolescents receiving different conditioning regimens for bone marrow transplantation.
    Giorgiani G; Bozzola M; Cisternino M; Locatelli F; Gambarana D; Bonetti F; Zecca M; Lorini R; Severi F
    Bone Marrow Transplant; 1991; 8 Suppl 1():53. PubMed ID: 1760641
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicities of total-body irradiation for pediatric bone marrow transplantation.
    Chou RH; Wong GB; Kramer JH; Wara DW; Matthay KK; Crittenden MR; Swift PS; Cowan MJ; Wara WM
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):843-51. PubMed ID: 8598361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
    Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth failure in children after total body irradiation preparative for bone marrow transplantation.
    Hovi L; Saarinen UM; Siimes MA
    Bone Marrow Transplant; 1991; 8 Suppl 1():10-3. PubMed ID: 1760625
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative toxicity of two different conditioning regimens in patients undergoing allogeneic bone marrow transplantation.
    Romeiras M; Rodrigues AS; Machado A; Jorge L; Nolasco I; Abecasis M
    Bone Marrow Transplant; 1991; 7 Suppl 2():133. PubMed ID: 1878678
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team.
    Sanders JE
    Semin Hematol; 1991 Jul; 28(3):244-9. PubMed ID: 1716003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of allogeneic bone marrow transplantation on the endocrine system in children.
    Dopfer R; Ranke MB; Einsele H; Ehninger G; Blum WF; Niethammer D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):541-5. PubMed ID: 2480305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine dysfunction after total body irradiation and bone marrow transplantation.
    Feyer P; Titlbach O; Hoffmann FA; Kubel M; Helbig W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):547-52. PubMed ID: 2480306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
    Kalaycioglu ME; Bolwell BJ
    Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
    Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation.
    Kanfer EJ; Buckner CD; Fefer A; Storb R; Appelbaum FR; Hill RS; Amos D; Doney KC; Clift RA; Shulman HM
    Bone Marrow Transplant; 1987 Apr; 1(4):339-46. PubMed ID: 3332142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
    Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.
    Teinturier C; Hartmann O; Valteau-Couanet D; Benhamou E; Bougneres PF
    Bone Marrow Transplant; 1998 Nov; 22(10):989-94. PubMed ID: 9849696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
    Lynch MH; Petersen FB; Appelbaum FR; Bensinger WI; Clift RA; Storb R; Sanders JE; Hansen JA; Buckner CD
    Bone Marrow Transplant; 1995 Jan; 15(1):59-64. PubMed ID: 7742756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.